NCT06639724 2026-04-07
Perioperative Fostamatinib With Gemcitabine and Nab-paclitaxel in Resectable Pancreatic Cancer
University of California, San Diego
Phase 1 Recruiting
Clinical Trials
17 trialsNCT05143970 2026-03-20
CHANCES
Institut Paoli-Calmettes
Phase 1 Recruiting
NCT06353646 2026-02-13
XH001 Combination With Immunocheckpoint Inhibitor and Chemotherapy for Patients With Resected Pancreatic Cancer
Peking Union Medical College Hospital
Phase NA Recruiting
NCT05723107 2025-11-28
EUS RFA for Treatment of Pancreatic Ductal Adenocarcinoma (PDAC)
NYU Langone Health
Phase 1 Recruiting
NCT03704662 2025-10-08
Preoperative Fractionated Radiation Therapy Versus Stereotactic Body Radiation Therapy for Resectable or Borderline Resectable, or Locally Advanced Type A Pancreatic Adenocarcinoma
Medical College of Wisconsin
Phase NA Recruiting
NCT06758544 2025-08-17
A Single-arm, Open-label Clinical Study to Evaluate the Efficacy and Safety of VRT106 in Combination With Chemotherapy for Resectable Pancreatic Cancer
Guangdong Provincial People's Hospital
Phase 1/2 Recruiting
NCT06691425 2025-08-08
TORPEDO
Cancer Research Antwerp
Phase NA Recruiting
NCT06307080 2025-07-09
Clinical Study of Multimodal Ablation Remodeling Immunosensitized PD-1 in the Treatment of Pancreatic Cancer With Liver Metastasis
Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine
Phase NA Recruiting
NCT06962267 2025-05-08
A Clinical Study on the First-line Treatment of Metastatic Pancreatic Cancer With TQB2916 Injection Combined With Gemcitabine Hydrochloride for Injection and Paclitaxel for Injection (Albumin-bound Type)
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
Phase 2 Recruiting
NCT06840067 2025-03-25
Clinical Study of Carbon Ion Radiotherapy for Pancreatic Cancer.
Gansu Wuwei Tumor Hospital
Phase NA Recruiting
NCT06344156 2025-02-28
Neoantigen Vaccine Plus Anti-PD1 and Chemotherapy as an Adjuvant Therapy for Pancreatic Cancer
Sichuan University
Phase 1 Recruiting
NCT06844422 2025-02-25
Adapted Guided Stereotactic Body Radiotherapy Combined with Chemotherapy and Enhancement of Novel Drug Ivonescimab for Pancreatic Cancer (ASCEND)
Shandong Cancer Hospital and Institute
Phase 1/2 Recruiting
NCT05462496 2024-10-15
Modulation of the Gut Microbiome With Pembrolizumab Following Chemotherapy in Resectable Pancreatic Cancer
Icahn School of Medicine at Mount Sinai
Phase 2 Recruiting
NCT03755739 2024-06-25
Trans-Artery/Intra-Tumor Infusion of Checkpoint Inhibitors Plus Chemodrug for Immunotherapy of Advanced Solid Tumors
Second Affiliated Hospital of Guangzhou Medical University
Phase 2/3 Recruiting
NCT06359275 2024-06-25
PD-1 Combined With Chemotherapy and PULSAR in LAPC and Local Recurrence Patients
Fudan University
Phase 2 Recruiting
NCT04638751 2024-04-05
ARGONAUT: Stool and Blood Sample Bank for Cancer Patients
Persephone Biosciences
Recruiting
NCT06326736 2024-03-22
Study of Neoantigen mRNA Vaccines in Patients With Resectable Pancreatic Cancer
Jinling Hospital, China
Phase EARLY_PHASE1 Recruiting